Vanguard Group Inc. Increases Position in Collegium Pharmaceutical, Inc. $COLL

Vanguard Group Inc. raised its position in Collegium Pharmaceutical, Inc. (NASDAQ:COLL) by 1.3% during the fourth quarter, HoldingsChannel reports. The firm owned 2,256,254 shares of the specialty pharmaceutical company’s stock after buying an additional 29,876 shares during the quarter. Vanguard Group Inc. owned 0.07% of Collegium Pharmaceutical worth $104,465,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of COLL. Massachusetts Financial Services Co. MA increased its position in shares of Collegium Pharmaceutical by 65.3% in the 4th quarter. Massachusetts Financial Services Co. MA now owns 1,312,655 shares of the specialty pharmaceutical company’s stock valued at $60,776,000 after purchasing an additional 518,721 shares during the last quarter. Millennium Management LLC increased its position in shares of Collegium Pharmaceutical by 248.5% in the 1st quarter. Millennium Management LLC now owns 647,832 shares of the specialty pharmaceutical company’s stock valued at $19,338,000 after purchasing an additional 461,914 shares during the last quarter. Assenagon Asset Management S.A. increased its position in shares of Collegium Pharmaceutical by 161.6% in the 4th quarter. Assenagon Asset Management S.A. now owns 511,698 shares of the specialty pharmaceutical company’s stock valued at $23,692,000 after purchasing an additional 316,109 shares during the last quarter. Two Sigma Investments LP boosted its holdings in shares of Collegium Pharmaceutical by 897.2% in the 3rd quarter. Two Sigma Investments LP now owns 269,318 shares of the specialty pharmaceutical company’s stock valued at $9,423,000 after buying an additional 242,310 shares in the last quarter. Finally, Qube Research & Technologies Ltd boosted its holdings in shares of Collegium Pharmaceutical by 237.9% in the 3rd quarter. Qube Research & Technologies Ltd now owns 320,559 shares of the specialty pharmaceutical company’s stock valued at $11,216,000 after buying an additional 225,679 shares in the last quarter.

Collegium Pharmaceutical Stock Down 0.3%

COLL stock opened at $35.69 on Wednesday. The company has a fifty day moving average price of $34.90 and a 200 day moving average price of $41.65. Collegium Pharmaceutical, Inc. has a 12 month low of $28.34 and a 12 month high of $50.79. The company has a market cap of $1.16 billion, a price-to-earnings ratio of 17.50 and a beta of 0.76. The company has a debt-to-equity ratio of 2.47, a current ratio of 1.71 and a quick ratio of 1.62.

Collegium Pharmaceutical (NASDAQ:COLL) last released its quarterly earnings results on Thursday, May 7th. The specialty pharmaceutical company reported $1.76 EPS for the quarter, beating the consensus estimate of $1.52 by $0.24. Collegium Pharmaceutical had a net margin of 9.41% and a return on equity of 95.18%. The firm had revenue of $193.52 million during the quarter, compared to the consensus estimate of $184.47 million. During the same quarter in the prior year, the firm earned $1.49 EPS. Collegium Pharmaceutical’s revenue for the quarter was up 8.9% on a year-over-year basis. Sell-side analysts expect that Collegium Pharmaceutical, Inc. will post 6.38 earnings per share for the current year.

Insider Transactions at Collegium Pharmaceutical

In related news, EVP David Dieter sold 13,976 shares of the firm’s stock in a transaction dated Wednesday, March 18th. The stock was sold at an average price of $34.92, for a total transaction of $488,041.92. Following the transaction, the executive vice president owned 77,071 shares of the company’s stock, valued at $2,691,319.32. This trade represents a 15.35% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, EVP Scott Dreyer sold 49,976 shares of the firm’s stock in a transaction dated Tuesday, March 3rd. The stock was sold at an average price of $40.41, for a total value of $2,019,530.16. Following the transaction, the executive vice president directly owned 71,770 shares in the company, valued at approximately $2,900,225.70. This represents a 41.05% decrease in their position. The SEC filing for this sale provides additional information. Company insiders own 1.85% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on the stock. HC Wainwright restated a “buy” rating and issued a $60.00 target price on shares of Collegium Pharmaceutical in a report on Friday, March 20th. Wall Street Zen upgraded shares of Collegium Pharmaceutical from a “buy” rating to a “strong-buy” rating in a report on Saturday. Weiss Ratings cut shares of Collegium Pharmaceutical from a “buy (b-)” rating to a “hold (c+)” rating in a report on Thursday, March 5th. Needham & Company LLC restated a “buy” rating and issued a $56.00 target price (up from $54.00) on shares of Collegium Pharmaceutical in a report on Thursday, March 19th. Finally, Truist Financial set a $58.00 target price on shares of Collegium Pharmaceutical in a report on Tuesday, February 10th. Four investment analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $57.50.

Collegium Pharmaceutical Profile

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on the development, manufacture and commercialization of products for pain management and opioid dependence. The company’s core expertise lies in its DETERx microsphere technology, a platform designed to provide extended-release delivery of active pharmaceutical ingredients while deterring manipulation for unintended routes of abuse.

The company’s principal marketed products include Xtampza® ER (extended-release oxycodone), which received approval from the U.S.